论文部分内容阅读
最近的研究表明Crohn氏病与非典型性分枝杆菌有关,一种利福平的新衍生物Rifabutin对这些微生物有高度活性。作者还证明手术后新形成终端回肠的Crohn氏病复发可作为研究对Crohn氏病药物的模型。作者报道16名患者(8男8女,平均年龄32岁),一年前都经过手术,治疗前均经内窥镜检查示有严重的新终端回肠损害。经Rifabutin(5mg/kg)和乙胺丁醇(15mg/kg)给药6个月。有6例因副作用撤出研究(副作用包括白血球减少、流感样症状)。剩下10例中7例完成治疗,但本研究证明,6个月的Rifabutin和乙胺丁醇联合治疗对复发性
Recent studies have shown that Crohn’s disease is associated with atypical mycobacteria, and Rifabutin, a new derivative of rifampicin, is highly active against these microorganisms. The authors also demonstrated that postoperative Crohn’s disease recurrence of newly formed terminal ileum could serve as a model for studying Crohn’s disease drugs. The authors reported 16 patients (8 males and 8 females, mean age 32 years) who underwent surgery a year ago and had severe terminal ileal damage by endoscopy before treatment. Rifabutin (5 mg / kg) and ethambutol (15 mg / kg) were administered for 6 months. There were 6 cases of withdrawal due to side effects (side effects include leukopenia, flu-like symptoms). The remaining 10 patients completed treatment in 7 cases, but this study demonstrated that 6 months of Rifabutin and ethambutol combined treatment of recurrent